Cobicistat-GS-9350-DataSheet-生命科學試劑-MedChemExpress_第1頁
Cobicistat-GS-9350-DataSheet-生命科學試劑-MedChemExpress_第2頁
Cobicistat-GS-9350-DataSheet-生命科學試劑-MedChemExpress_第3頁
Cobicistat-GS-9350-DataSheet-生命科學試劑-MedChemExpress_第4頁
全文預覽已結束

下載本文檔

版權說明:本文檔由用戶提供并上傳,收益歸屬內容提供方,若內容存在侵權,請進行舉報或認領

文檔簡介

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemECobicistatCat.No.:HY-10493CASNo.:1004316-88-4Synonyms:GS-9350分?式:C??H??N?O?S?分?量:776.02作?靶點:CytochromeP450;HIV作?通路:MetabolicEnzyme/Protease;Anti-infection儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數據體外實驗DMSO:250mg/mL(322.16mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲備液1mM1.2886mL6.4431mL12.8863mL5mM0.2577mL1.2886mL2.5773mL10mM0.1289mL0.6443mL1.2886mL請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;?旦配成溶液,請分裝保存,避免反復凍融造成的產品失效。儲備液的保存?式和期限:-80°C,6months;-20°C,1month。-80°C儲存時,請在6個?內使?,-20°C儲存時,請在1個?內使?。體內實驗請根據您的實驗動物和給藥?式選擇適當的溶解?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液,再依次添加助溶劑:(為保證實驗結果的可靠性,澄的儲備液可以根據儲存條件,適當保存;體內實驗的?作液,建議您現?現配,當天使?;以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?;如在配制過程中出現沉淀、析出現象,可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑:10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:≥2.08mg/mL(2.68mM);Clearsolution2.請依序添加每種溶劑:10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.08mg/mL(2.68mM);Clearsolution3.請依序添加每種溶劑:10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(2.68mM);ClearsolutionBIOLOGICALACTIVITY?物活性Cobicistat有效,選擇性的細胞?素酶P4503A(CYP3A)抑制劑,IC50值為30-285nM。Cobicistat?種藥代動?學增強劑,可增強抗HIV藥物的吸收。IC50&TargetIC50:30-285nM(CytochromeP450)[1]體外研究InHIV-1proteaseenzymaticassayandantiviralcellularassays.CobicistatisinactiveagainstHIV-1protease(IC50>30μM).AndCobicistathasnoinhibitoryeffectagainstHIVreplicationinamulticycle5-dayMT-2HIVinfectionassay(EC50>30μM).InassaysusingMT-2cells,Cobicistatexhibitsminimalcytotoxicity,withaCC50valueabove80μM[1].ThemodeofinhibitionofhumanCYP3AbyCobicistatandRitonavirsharesthesamemechanismofactionfortheinhibitionofCYP3A.ItshowsitsinhibitoryeffectsonCYP3AmayinvolvedirectlyatthehemegroupoftheCYP3Aenzyme[1].TheminimaladverseeffectsofCobicistatintheseassayssuggestalowerpotentialfortoxicityrelatedtoalteredlipidmetabolism.Inthelipidaccumulationassaywiththehumanadipocytes,RitonavirshowsacleareffectwithanEC50of16μM.However,Cobicistatexhibitsnoeffectataconcentrationupto30μM[1].Intheglucoseuptakeassaywithmouseadipocytes,Ritonavirshowsapronouncedeffectattheconcentrationof10μM.Incontrast,theeffectsonglucoseuptakebyCobicistat(10μM)issignificantlyless[1].PROTOCOLKinaseAssay[1]InhibitionofhumancytochromeP450activitiesisdeterminedinduplicateinpooledhumanhepaticmicrosomalfractionsfollowingcurrentscientificandregulatoryguidelines.Reactionconditionsarelinearwithrespecttoincubationtimeandhepaticmicrosomalproteinconcentration.SubstratesarepresentatconcentrationsequaltoorlessthantheirrespectiveKmvaluesdeterminedunderthesamereactionconditions.Metaboliteand/orsubstrateconcentrationsaredeterminedusingspecific,internalstandardcontrolledHPLCMS/MSassays.Forreactionsmonitoringmetaboliteformationthereislessthan20%consumptionofsubstrateduringthereaction.Unlessotherwisenotedmicrosomalfraction,dilutedinpotassiumphosphatebuffer,ispreincubatedwithsubstrateandinhibitorfor5minat37°CandthereactioninitiatedbytheadditionofanNADPHgeneratingsystemfollowedbyfurtherincubationat37°Cwithshaking.Enzyme-selectivepositivecontrolinhibitorsaretestedinparallel.Atappropriatetimesaliquotsofthemixtureareremovedandthereactionterminatedbyadditiontoamixtureofmethanolandacetonitrilecontainingtherespectiveinternalstandard.AftercentrifugationaliquotsofthesupernatantaresubjectedtoHPLC-MS/MSanalysis.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemECellAssay[1]Five-foldserialdilutionsofthetestedcompoundsarepreparedintriplicatein96-wellplates.MT-2cellsareaddedtoplatesatadensityof20,000/wellinafinalassayvolumeof200μL.Aftera5-dayincubationat37°C,thecytotoxiceffectisdeterminedusingacellviabilityassay.OnehundredμLmediaisremovedfromeachwellandreplacedwith100μLofphosphate-bufferedsalinecontaining1.7mg/mLXTTand5μg/mLPMS.Following1-hourincubationat37°C,20μLof2%TritonX-100isaddedtoeachwellandabsorbanceisreadat450nmwithabackgroundsubtractionat650nm.Thedataareplottedascellviabilityvs.drugconcentration.Cellviabilityisexpressedasapercentageofthesignalfromuntreatedsamples(0%cytotoxicity)afterthesubtractionofsignalfromsamplestreatedwith10μMofPodophyllotoxin(100%cytotoxicity).TheCC50valueiscalculatedfromtheinhibitionplotsastheconcentrationofdrugwhichinhibitscellproliferationby50%.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.戶使?本產品發(fā)表的科研?獻?ActaPharmSinB.2021Mar22.?ActaPharmSinB.2020Aug.?EurJMedChem.2020Oct15;204:112626.?EurJMedChem.2020Aug15;200:112427.?Viruses.2020Apr16;12(4):452.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].LianhongXu,etal.Cobicistat(GS-9350):APotentandSelectiveInhibitorofHumanCYP3AasaNovelPharmacoenhancer.ACSMed.Chem.Lett.,2010,1(5),pp209–213[2].TemesgenZ.Cobicistat,apharmacoenh

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯系上傳者。文件的所有權益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網頁內容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
  • 4. 未經權益所有人同意不得將文件中的內容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網僅提供信息存儲空間,僅對用戶上傳內容的表現方式做保護處理,對用戶上傳分享的文檔內容本身不做任何修改或編輯,并不能對任何下載內容負責。
  • 6. 下載文件中如有侵權或不適當內容,請與我們聯系,我們立即糾正。
  • 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論